July to September
- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -5.3 (-6.1), corresponding to earnings per share of
SEK -0.09 (-0.11)
- Cash flow after financing activities amounted to MSEK -6.1 (+39.1)
- Cash amounted to MSEK 23.5 (52.1), compared to MSEK 45.3 on
31 December 2021
January to September
- Net sales amounted to MSEK 0 (0)
- Net loss was MSEK -19.9 (-21.1), corresponding to earnings per share of
SEK -0.33 (-0.49)
- Cash flow after financing activities amounted to MSEK -21.8 (-27.9)
Significant events during January – September
- In
January 2022 , warrants corresponding to a dilution of 0.2% of the number of outstanding shares were deregistered.
- In
February 2022 , the first trial person was enrolled in PHSU05 (ensereptide).
- The recruitment target for the study was achieved according to plan in March.
- At the AGM in May, Marianne Dicander Alexandersson was elected new chairman of the board. Also,
Candice Jung was elected new member of the board.
- In
September 2022 , the last clinic visit in PHSU05 occurred (ensereptide).
- In
August 2022 , the company received a granted patent in theEuropean Union for the use of the candidate drug ropo-camptide (LL-37) for the treatment of chronic wounds.
Events after the reporting period
- In
November 2022 , it was announced that results from PHSU05 are expected inApril 2023 , where the lack of special-ized staff and equipment is the reason for the slight delay
” The third quarter of the year has been characterized by continued progress within our two clinical development programs”
© Modular Finance, source